Dapiglutide is an investigational once-weekly long-acting GLP-1/GLP-2 dual receptor agonist from Zealand Pharma. Early Phase 1/2 data showed 8 to 11 percent weight loss over 13 weeks. It sits earlier in development than other emerging incretin drugs and is not FDA approved. Clinical trial participation is the only current access route.
What Dapiglutide Is
Dapiglutide (development code ZP7570) is a synthetic peptide engineered as a single molecule that activates two receptors:
- GLP-1 receptor — appetite suppression, slowed gastric emptying, glucose-dependent insulin release
- GLP-2 receptor — intestinal epithelial growth and proliferation, mucosal barrier function, anti-inflammatory effects in the gut
It is administered as a once-weekly subcutaneous injection with gradual dose titration. Zealand Pharma is the originator; the program also explores oral peptide co-administration in some studies.
The GLP-2 Angle
GLP-2 is a peptide hormone released from intestinal L-cells alongside GLP-1. It acts mainly locally on the gut:
- Stimulates intestinal crypt cell proliferation and villus growth
- Improves mucosal barrier function (reduces “leaky gut”)
- Reduces gut-derived inflammatory signals
- Slows gastric emptying
- Decreases intestinal permeability to endotoxin
Teduglutide, a GLP-2 analog, is already approved for short bowel syndrome. The hypothesis for dapiglutide is that combining GLP-1 (for appetite and glucose) with GLP-2 (for intestinal barrier and anti-inflammatory effects) could produce a metabolic drug with distinct benefits — possibly including effects on metabolic endotoxemia, MASH, and obesity-associated gut inflammation.
Early Clinical Data
Dapiglutide is earlier in development than other Phase 3 incretin agents.
| Trial phase | Population | Duration | Findings |
|---|---|---|---|
| Phase 1 | Healthy volunteers | Single/multiple ascending dose | Acceptable tolerability; PK supports weekly dosing |
| Phase 1b/2a | Adults with overweight/obesity | 13 weeks | ~8-11% weight loss at top dose; class-typical GI side effects |
| Phase 2 | Obesity (longer duration) | Ongoing | Readout expected 2025-2026 |
These short-duration figures look promising but cannot be directly compared with 68-week semaglutide or tirzepatide trial results.
How Dapiglutide Compares
| Drug | Mechanism | Stage (2026) | Notable differentiator |
|---|---|---|---|
| Semaglutide | GLP-1 | Approved | Established CV and weight outcomes |
| Tirzepatide | GLP-1 + GIP | Approved | Strong weight loss |
| Retatrutide | GLP-1 + GIP + glucagon | Phase 3 | Highest weight-loss signal |
| Survodutide | GLP-1 + glucagon | Phase 3 | MASH |
| Dapiglutide | GLP-1 + GLP-2 | Phase 2 | Intestinal barrier + appetite |
Side Effects
The early dapiglutide safety profile resembles the GLP-1 class:
- Nausea — most common, especially during dose escalation
- Vomiting
- Diarrhea
- Constipation
- Decreased appetite
- Mild fatigue
- Injection site reactions
An additional theoretical concern for any GLP-2 agent is intestinal cellular proliferation — important for short bowel patients but also requiring long-term monitoring for any neoplastic signal. Early dapiglutide data do not show such a signal, but Phase 2 and Phase 3 trials with longer duration will be the test.
Potential Indications
Possible directions for dapiglutide development based on its mechanism:
- Obesity (primary current focus)
- Type 2 diabetes
- Metabolic dysfunction-associated steatohepatitis (MASH)
- Inflammatory bowel disease or other intestinal-barrier conditions
- Short bowel syndrome (would compete with teduglutide)
- Cardiometabolic disease with prominent gut inflammation
Most of these are speculative until trials read out. The primary commercial focus is obesity in adults.
Timeline to Possible Approval
Dapiglutide is several years behind retatrutide and survodutide. A reasonable expectation is:
- Phase 2 readouts: 2025-2026
- Phase 3 trials: starting 2026-2027
- FDA submission: 2028-2029 if Phase 3 succeeds
- Possible approval: 2029-2030
These timelines depend on full Phase 2 results and the development partner Zealand chooses.
Cost and Access
No price exists — dapiglutide is investigational. The only current access is enrollment in a clinical trial. Compounded dapiglutide does not legally exist. Searching ClinicalTrials.gov for “dapiglutide” returns active studies and contact information for enrolling sites.
Where It Fits Among Emerging Therapies
Dapiglutide is the most distinct of the next-generation incretin drugs by mechanism, focusing on the gut rather than central appetite or fat oxidation. It develops alongside retatrutide, orforglipron, CagriSema, and survodutide. For background on existing options and diet support, see our pages on treatment and diet and nutrition.
Open Questions
- Long-term weight loss past 6 to 12 months
- Whether GLP-2 provides clinically measurable advantages beyond GLP-1 alone
- Any neoplastic monitoring needed for GLP-2 component
- Effects on biomarkers of intestinal barrier function (zonulin, LPS)
- Cardiovascular outcomes
- MASH and IBD studies — currently hypothetical
What to Discuss with a Clinician
- Whether enrolling in a clinical trial is reasonable given current health status
- What approved therapies (semaglutide, tirzepatide, liraglutide) have been tried
- Personal history of gastrointestinal disease, neoplasm, or pancreatitis
- Realistic timelines for any new drug to reach commercial availability
The Bottom Line
Dapiglutide is an investigational once-weekly GLP-1/GLP-2 dual receptor agonist from Zealand Pharma, sitting in Phase 2 development. Early data show 8 to 11 percent weight loss over 13 weeks and class-typical gastrointestinal side effects. Its differentiator is the GLP-2 component — adding intestinal-barrier and anti-inflammatory effects not seen in other incretin drugs. It is years from possible FDA approval and currently available only through clinical trials. Talk to your clinician about approved alternatives or trial enrollment if you are interested in early-stage incretin therapy.
